Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid...(diseases such as rheumatoid arthritis th...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Date:7/8/2009
diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.com
'/>"/>
| SOURCE Rigel Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine technology :
1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
Breaking Medicine Technology:ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3New lab test offers better prediction of HIV microbicide safety 9203 1New lab test offers better prediction of HIV microbicide safety 9203 2New lab test offers better prediction of HIV microbicide safety 9203 3Exploring standards to advance microbial genomics 9201 1Exploring standards to advance microbial genomics 9201 2Exploring standards to advance microbial genomics 9201 3Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 1Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 2Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 3
Other Medicine Technology:QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web 2Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 7
Breaking Medicine News(10 mins):Health News:PROVERI, Inc. Named a Top Innovator Winner 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 3Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 4Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2
[0] PROVERI, Inc. Named a Top Innovator Winner[0] Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems[0] Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies[0] Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing[0] Wellness Manufacturer Wins Two 2009 American Spa Awards
Other Medicine News:Health News:First Time Federal Funding for Mesothelioma Research 2Health News:Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution 2Health News:Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution 3Health News:Pennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Children's Health Care 2Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 2Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 3Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 4Health News:Peripheral Arterial Disease Costlier to Treat Than Heart Trouble 2Health News:New method enables design, production of extremely novel drugs 2Health News:New method enables design, production of extremely novel drugs 3
First Time Federal Funding for Mesothelioma ResearchSiemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy SolutionPennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Children's Health CareNine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare FraudPeripheral Arterial Disease Costlier to Treat Than Heart TroubleNew method enables design, production of extremely novel drugs
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |